Pharmaceutical Standard Lexicon

History

2022: Pharmstandard invests 1.9 billion rubles in doubling paracetomol production

As it became known in May 2022, hhFarmstandard will invest 1.9 billion rubles in doubling the production of paracetomol at the plant in Kursk (OJSC Pharmstandart-Lexedeles). This was announced by the press service of the administration of the Kursk region following a meeting between the governor of the region Roman Starovoit and the general director of Pharmstandart Vladimir Kreiman.

The company is implementing a major investment project to organize a site of solid dosage forms. Pharmstandard will invest in the creation in Kursk of "widely known and often used tablets," such as Askofen-P and Citramone P with MHH acetylsalicylic acid + caffeine + paracetamol, validol and other drugs. According to representatives of the administration of the Kursk region, in order to meet market demands, it is necessary to transfer the production of drugs with these and other MNS to large-scale production. It is assumed that the capacity of the enterprise will be 400 million packages per year, which will allow the plant to almost double the volumes in the existing nomenclature. In 2021, according to the regional administration, 544.3 million packages of drugs worth 35.7 billion rubles were produced.

Pharmstandard invests 1.9 billion rubles in doubling paracetomol production

In general, the "large-scale program for the development of the enterprise until 2030" includes the reconstruction of the entire production, said Vladimir Kreiman, whose words are quoted by Kommersant. As part of it, it is planned to increase the number of employees to 4 thousand people (by May 2022 - more than 2 thousand) and introduce another 30 thousand square meters of production space.

By May 2022, OJSC Pharmstandard-Lexedstvo produces about 500 types of drugs, "including import substitutes." It is noted that in January-April 2022 the volume of production by 28% exceeded the indicator of the same period of 2021.^[1]

Notes